Study protocol for the DETECTIVE study: an international collaborative study to develop consensus statements for deferred treatment with curative intent for localised prostate cancer.

Lam, Thomas B.L.; MacLennan, Steven; Plass, Karin; Willemse, Peter-Paul M.; Mason, Malcolm D.; Cornford, Philip; Donaldson, James; Davis, Niall F.; Dell'Oglio, Paolo; Fankhauser, Christian; Grivas, Nikos; Ingels, Alexandre; Lardas, Michael; Liew, Matthew; Pang, Karl H.; Paterson, Catherine; Omar, Muhammad I.; Zattoni, Fabio; Buddingh, Karel T.; Van den Broeck, Thomas; Cumberbatch, Marcus G.; Fossati, Nicola; Gross, Tobias; Moris, Lisa; Schoots, Ivo G.; van den Bergh, Roderick C.N.; Briers, Erik; Fanti, Stefano; De Santis, Maria; Gillessen, Silke; Grummet, Jeremy P.; Henry, Ann M.; van der Poel, Henk G.; van der Kwast, Theodorus H.; Tilki, Derya; Wiegel, Thomas; N'Dow, James; Van Poppel, Hendrik; Mottet, Nicolas

doi:10.1016/j.eururo.2018.11.009

Study protocol for the DETECTIVE study: an international collaborative study to develop consensus statements for deferred treatment with curative intent for localised prostate cancer.

Authors

Thomas B.L. Lam

Steven MacLennan

Karin Plass

Peter-Paul M. Willemse

Malcolm D. Mason

Philip Cornford

James Donaldson

Niall F. Davis

Paolo Dell'Oglio

Christian Fankhauser

Nikos Grivas

Alexandre Ingels

Michael Lardas

Matthew Liew

Karl H. Pang

Catherine Paterson

Muhammad I. Omar

Fabio Zattoni

Karel T. Buddingh

Thomas Van den Broeck

Marcus G. Cumberbatch

Nicola Fossati

Tobias Gross

Lisa Moris

Ivo G. Schoots

Roderick C.N. van den Bergh

Erik Briers

Stefano Fanti

Maria De Santis

Silke Gillessen

Jeremy P. Grummet

Ann M. Henry

Henk G. van der Poel

Theodorus H. van der Kwast

Olivier

Derya Tilki

Thomas Wiegel

James N'Dow

Hendrik Van Poppel

Nicolas Mottet

Abstract

Deferred active treatment (DAT) strategies, including active surveillance and active monitoring, are a recognised management option for men with localised low-risk prostate cancer. However, there is uncertainty due to heterogeneity of patient selection criteria, follow-up and monitoring characteristics, reclassification thresholds, and which outcome measures should be prioritised. This protocol describes a study led by the European Association of Urology (EAU) Prostate Cancer Guidelines Panel in conjunction with other guideline organisations and societies to develop consensus statements for all domains of deferred active treatment. The project is divided into 3 sequential phases: (1) Systematic review of studies reporting on DAT in order to summarise and define range of heterogeneity regarding all domains; (2) Two-round Delphi online survey involving a large, international panel of healthcare professionals (HCPs) and patients to initiate consensus; and (3) Consensus group meeting involving representatives from HCP and patient stakeholder groups to finalise the consensus process. The consensus statements are expected to be adopted by clinical practice guidelines in order to standardise and guide practice for clinicians and researchers until better evidence emerges. Patient summary: We describe a project aimed at standardising elements of practice in active surveillance/monitoring for early localised prostate cancer, because currently there is great variation and uncertainty regarding how best to conduct them. This will be achieved through a structured process of agreement (i.e. consensus) amongst a large, international panel of healthcare professionals and patients.

Citation

LAM, T.B.L., MACLENNAN, S., PLASS, K. et al. 2019. Study protocol for the DETECTIVE study: an international collaborative study to develop consensus statements for deferred treatment with curative intent for localised prostate cancer. European urology [online], 75(4), pages 699-702. Available from: https://doi.org/10.1016/j.eururo.2018.11.009

Journal Article Type	Article
Acceptance Date	Nov 2, 2018
Online Publication Date	Nov 22, 2018
Publication Date	Apr 30, 2019
Deposit Date	Nov 12, 2018
Publicly Available Date	Nov 23, 2019
Journal	European urology
Print ISSN	0302-2838
Electronic ISSN	1873-7560
Publisher	Elsevier
Peer Reviewed	Peer Reviewed
Volume	75
Issue	4
Pages	699-702
DOI	https://doi.org/10.1016/j.eururo.2018.11.009
Keywords	Deferred active treatment; Prostate cancer; Men; Clinical practice guidelines
Public URL	http://hdl.handle.net/10059/3214